http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 21 Jul 2025 14:58:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Virpax+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/25075355.html si-local-file:///var/storage/secattach/20250721/25075355.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Virpax+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/25075355.html Mon, 21 Jul 2025 14:58:00 -0400 O.40308091 VRPX http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Virpax+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/25075355.html si-local-file:///var/storage/secattach/20250721/25075355.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Virpax+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/25075355.html Mon, 21 Jul 2025 14:58:00 -0400 O.40308091 VRPX http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Virpax+Pharmaceuticals%2C+++For%3A+Apr+02/24598959.html si-local-file:///var/storage/secattach/20250403/24598959.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Virpax+Pharmaceuticals%2C+++For%3A+Apr+02/24598959.html Thu, 03 Apr 2025 17:01:00 -0400 O.40308091 VRPX http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Virpax+Pharmaceuticals%2C+++For%3A+Apr+02/24598959.html si-local-file:///var/storage/secattach/20250403/24598959.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Virpax+Pharmaceuticals%2C+++For%3A+Apr+02/24598959.html Thu, 03 Apr 2025 17:01:00 -0400 O.40308091 VRPX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Virpax+Pharmaceuticals%2C+++For%3A+Apr+02/24596193.html si-local-file:///var/storage/secattach/20250403/24596193.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Virpax+Pharmaceuticals%2C+++For%3A+Apr+02/24596193.html Thu, 03 Apr 2025 11:01:00 -0400 O.40308091 VRPX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Virpax+Pharmaceuticals%2C+++For%3A+Apr+02/24596193.html si-local-file:///var/storage/secattach/20250403/24596193.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Virpax+Pharmaceuticals%2C+++For%3A+Apr+02/24596193.html Thu, 03 Apr 2025 11:01:00 -0400 O.40308091 VRPX http://www.streetinsider.com/SEC+Filings/Form++S-1A++++++Virpax+Pharmaceuticals%2C++++++++++++++/24541927.html si-local-file:///var/storage/secattach/20250325/24541927.html http://www.streetinsider.com/SEC+Filings/Form++S-1A++++++Virpax+Pharmaceuticals%2C++++++++++++++/24541927.html Tue, 25 Mar 2025 06:11:00 -0400 O.40308091 VRPX http://www.streetinsider.com/SEC+Filings/Form++S-1A++++++Virpax+Pharmaceuticals%2C++++++++++++++/24541927.html si-local-file:///var/storage/secattach/20250325/24541927.html http://www.streetinsider.com/SEC+Filings/Form++S-1A++++++Virpax+Pharmaceuticals%2C++++++++++++++/24541927.html Tue, 25 Mar 2025 06:11:00 -0400 O.40308091 VRPX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Virpax+Pharmaceuticals%2C+++For%3A+Mar+21/24534978.html si-local-file:///var/storage/secattach/20250321/24534978.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Virpax+Pharmaceuticals%2C+++For%3A+Mar+21/24534978.html Fri, 21 Mar 2025 17:21:00 -0400 O.40308091 VRPX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Virpax+Pharmaceuticals%2C+++For%3A+Mar+21/24534978.html si-local-file:///var/storage/secattach/20250321/24534978.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Virpax+Pharmaceuticals%2C+++For%3A+Mar+21/24534978.html Fri, 21 Mar 2025 17:21:00 -0400 O.40308091 VRPX http://www.streetinsider.com/Stock+Splits/Virpax+Pharmaceuticals+%28VRPX%29+Announces+1%3A25+Reverse+Share+Split/24520420.html <p>Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis when the Nasdaq opens on March http://www.streetinsider.com/Stock+Splits/Virpax+Pharmaceuticals+%28VRPX%29+Announces+1%3A25+Reverse+Share+Split/24520420.html Wed, 19 Mar 2025 08:00:26 -0400 VRPX http://www.streetinsider.com/Corporate+News/Virpax+Pharmaceuticals+%28VRPX%29+Announces+1%3A25+Reverse+Share+Split/24520420.html <p>Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis when the Nasdaq opens on March http://www.streetinsider.com/Corporate+News/Virpax+Pharmaceuticals+%28VRPX%29+Announces+1%3A25+Reverse+Share+Split/24520420.html Wed, 19 Mar 2025 08:00:26 -0400 VRPX http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Press+Releases/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html <p> BERWYN, Pa.--(BUSINESS WIRE)-- Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on March 20, 2025. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “VRPX” and will begin trading on a split-adjusted basis http://www.streetinsider.com/Business+Wire/Virpax+Pharmaceuticals+Announces+Reverse+Stock+Split/24520346.html Wed, 19 Mar 2025 08:00:00 -0400 A.09642568 A.19655944 A.40958841 O.03307993 O.20371933 O.36670513 O.40308091 VRPX